 PALO ALTO, Calif., Jan. 06, 2021 GLOBE NEWSWIRE -- BridgeBio Pharma, Inc. Nasdaq: BBIO, a clinical-stage biopharmaceutical company focused on genetic diseases, today announced that on January 4, 2021, the compensation committee of BridgeBios board of directors granted six new employees restricted stock units for an aggregate of 4,126 shares of the Companys common stock. All of the above-described awards were made under BridgeBios 2019 Inducement Equity Plan the Plan. 